Dan Karelitz is a partner in the firm's Business Law Department and a member of the Tax practice. Mr. Karelitz has strong general tax experience, advising sponsors on fund formation and portfolio company acquisition, disposition, and restructuring matters in the technology, private equity and real estate spaces. In addition, borrowing on deep experience in the private equity and real estate transaction space, and combined with his background as an organic chemist, Mr. Karelitz has a particular focus on the Life Sciences sector advising clients on structuring their operations, strategic transactions, acquisitions and divestitures in a tax-efficient manner.

He joined Goodwin in 2007.

Areas of Practice
TÄTIGKEITSFELDER
Domaines D’Expertise
业务范围
Tax

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Representative Matters

REFERENZMANDATE

代表事项

Public Offerings
  • Fusion Pharmaceuticals in its $212.5 million initial public offering
  • Moderna Therapeutics in its $604 million initial public offering; $500 million follow-on offering; and $1.34 million follow-on offering
  • Black Diamond Therapeutics in its $231.3 million initial public offering
  • Xeris Pharmaceuticals in its concurrent $89.3 million offering of common stock and convertible senior notes
  • Immatics, N.V. in its ~$1 billion business combination with ARYA Sciences Acquisition Corp. and listing on Nasdaq
  • BridgeBio Pharma in its $372.7 million initial public offering
  • Ascentage Pharma in its $61 million initial public offering on the HKSE
  • Avadel Pharmaceuticals in its $65 million financing transaction and its $125 million follow-on public offering
  • BeiGene in the sale of $2.8 billion of shares to Amgen
  • Orchard Therapeutics in its $225 million initial public offering
  • AquaVenture Holdings in its $117 million initial public offering
  • Intellia Therapeutics in its $108 million initial public offering
  • CRISPR Therapeutics in its $56 million initial public offering and its $200 million follow-on offering
Convertible Notes
  • Inseego Corp. in its offering of $100 million in convertible senior notes
  • Cerence, Inc. in its offering of $175 million in convertible senior notes
  • HubSpot, Inc. in its offering of $460 million in convertible senior notes
  • Health Catalyst in its offering of $200 million in convertible senior notes
  • Model N, Inc. in its offering of $150 million in convertible senior notes
  • Everbridge, Inc. in its offering of $450 million in convertible senior notes
  • Slack Technologies in its offering of $750 million in convertible senior notes
  • RingCentral in its offering of $1 billion in convertible senior notes
  • Zendesk in its offering of $1.15 billion in convertible senior notes
  • Otka in its offering of $1 billion in convertible senior notes
  • Varonis Systems in its offering of $220 million in convertible senior notes
  • 2U, Inc. in its offering of $380 million in convertible senior notes
Private Financings
  • Thrive Earlier Detection Corp. in its $110 million Series A financing and Galecto in its $40 million Series C financing
  • Cullinan Oncology in its $100 million Series B financing
  • ElevateBio in its $170 million Series B financing 
  • Moderna Therapeutics in its $110 million Series D financing and $500 million Series E financing
  • Intellia Therapeutics in its $15 million Series A financing and $70 million Series B financing
  • Nimbus Therapeutics in its $43 million Series B financing and $65 million Series C financing
  • Scholar Rock in its $36 million Series B financing and $47 million Series C financing
  • Cullinan Oncology in its $150 million Series A financing
  • Kymera Therapeutics in its $30 million Series A financing
  • Ginkgo Bioworks in its agreement with Bayer to launch JoynBio for $100 million Series A investment
Strategic Collaborations and M&A
  • Moderna in its strategic collaboration with Lonza Ltd.
  • Alnylam Pharmaceuticals in its $2 billion strategic collaboration with Blackstone; and in its development and commercialization collaboration with Dicerna Pharmaceuticals
  • Promedior, Inc in its ~$1 billion definitive merger agreement with Roche
  • Yantriks in its sale to Blue Yonder Group
  • AquaVenture in its $1.1 billion sale to Culligan
  • Backstone Life Sciences in its collaboration with Ferring Pharmaceuticals for $570 million
  • Semma Therapeutics in its $950 million sale to Vertex Pharmaceuticals
  • BlueRock Therapeutics in its $1 billion sale to Bayer AG
  • CRISPR Therapeutics in its strategic transaction with Bayer HealthCare to form Casebia Therapeutics; and subsequently in connection to the unwind of Casebia Therapeutics
  • Teva Pharmaceuticals in its $3.2 billion acquisition of Auspex Pharmaceuticals
  • Versant Ventures in its strategic transaction with Bayer to form BlueRock Therapeutics, with a combined financing amount of $225 million
  • Foundation Medicine in its strategic collaboration with Roche, valued at more than $1 billion, and subsequent $2.2 billion merger with Roche
  • Quartet Medicine in its $595 million strategic collaboration with Merck
  • Nimbus Therapeutics in its sale of Nimbus Apollo to Gilead, with $400 million upfront and the potential to receive an additional $800 million over time and strategic alliance with Celgene Corporation in immunology
  • CRISPR Therapeutics in its collaboration with Bayer, valued up to $335 million upfront
  • Padlock Therapeutics in its $225 million sale to Bristol Myers Squibb
  • F-star Alpha in its agreement with Bristol-Myers Squibb
  • Moderna Therapeutics in its collaboration with AstraZeneca to co-develop and co-commercialize immune-oncology mRNA Therapeutics 
  • Warp Drive Bio in its acquisition by Revolution Medicines
  • Sage Therapeutics in its collaboration with Shionogi for $90 million up front and potential deal value in excess of $575 million
  • Pairwise Plants in its collaboration with Monsanto to advance agriculture research and development by leveraging gene editing technology for $100 million
  • Alnylam Pharmaceuticals on its strategic restructuring of its RNAi therapeutics alliance with Sanofi

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 2008
Georgetown University

(magna cum laude, Order of the Coif)

M.S., 2004
Emory University
B.S., 2004
Emory University

(Phi Beta Kappa)

Admissions

Bar

Massachusetts
Profile Image
Get In Touch
Kontakt
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师
Tax